Literature DB >> 11358513

Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3.

S Réhault1, P Monget, S Mazerbourg, R Tremblay, N Gutman, F Gauthier, T Moreau.   

Abstract

Insulin-like growth factors (IGFs) are important growth regulators of both normal and malignant prostate cells. Their action is regulated by six insulin-like growth factor binding proteins (IGFBPs). The proteolytic cleavage of IGFBPs by various proteases decreases dramatically their affinity for their ligands and therefore enhances the bioavailability of IGFs. To elucidate the putative biological role of prostatic kallikreins hK2 and hK3 (prostate-specific antigen) in tumour progression, we analyzed the degradation of IGFBP-2, -3, -4 and -5 by these two tissue kallikreins. We found that hK3, already characterized as an IGFBP-3 degrading protease, cleaved IGFBP-4 but not IGFBP-2 and -5, whereas hK2 cleaved all of the IGFBPs much more effectively, and at concentrations far lower than those reported for other IGFBP-degrading proteases. The proteolytic patterns after cleavage of IGFBPs by hK2 and hK3 were similar and were not modified in the presence of IGF-I. Heparin, but not other glycosaminoglycans, enhanced dramatically the ability of hK3 but not hK2 to degrade IGFBP-3 and IGFBP-4. More importantly, the IGFBP fragments generated by hK2 and hK3 had no IGF-binding capacity, as assessed by Western ligand blotting. Our results suggest that the prostatic kallikreins hK2 and hK3 may influence specifically the tumoral growth of prostate cells through the degradation of IGFBPs, to increase IGF bioavailability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358513     DOI: 10.1046/j.1432-1327.2001.02185.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

Review 1.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

Review 2.  Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Authors:  Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras
Journal:  Crit Rev Oncog       Date:  2015

3.  Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.

Authors:  Taichi Kimura; Takeshi Kuwata; Satoshi Ashimine; Manabu Yamazaki; Chisako Yamauchi; Kanji Nagai; Akashi Ikehara; Yang Feng; Dimiter S Dimitrov; Seiichi Saito; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 4.  Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Authors:  Daniel L J Thorek; Michael J Evans; Sigrid V Carlsson; David Ulmert; Hans Lilja
Journal:  Thromb Haemost       Date:  2013-08-01       Impact factor: 5.249

5.  Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.

Authors:  Jeremy G Stone; Raj K Rolston; Masumi Ueda; Hyoung-Gon Lee; Sandy L Richardson; Rudy J Castellani; George Perry; Mark A Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-10-20

6.  "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response.

Authors:  Adaikkalam Vellaichamy; Zoltán Dezso; Lellean JeBailey; Arul M Chinnaiyan; Arun Sreekumar; Alexey I Nesvizhskii; Gilbert S Omenn; Andrej Bugrim
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

7.  Human seminal proteinase and prostate-specific antigen are the same protein.

Authors:  Abdul Waheed; Md Imtaiyaz Hassan; Robert L Van Etten; Faizan Ahmad
Journal:  J Biosci       Date:  2008-06       Impact factor: 1.826

Review 8.  IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Authors:  Claire M Perks; Jeff M P Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

9.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

10.  Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.

Authors:  A J Ryan; S Napoletano; P A Fitzpatrick; C A Currid; N C O'Sullivan; J H Harmey
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.